Vaccinations have been completed and Valneva expects VALOR trial outcomes to be announced in the first half of 2026, followed by regulatory submissions as planned. Pfizer aims to submit a Biologics ...
Despite undertaking a capital increase that raised 27.4 million euros, the company's financial foundation continues to weaken. Shareholders' equity has now dwindled to just 150.5 million euros, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback